Stereotactic ablative radiation therapy for primary lung tumors

John H. Heinzerling, Brian Kavanagh, Robert D. Timmerman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalCancer Journal
Volume17
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Radiotherapy
Lung
Neoplasms
Investigational Therapies
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Therapeutics

Keywords

  • innovative therapy
  • non-small cell lung cancer (NSCLC)
  • stage I lung cancer
  • Stereotactic ablative radiotherapy (SABR)
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stereotactic ablative radiation therapy for primary lung tumors. / Heinzerling, John H.; Kavanagh, Brian; Timmerman, Robert D.

In: Cancer Journal, Vol. 17, No. 1, 01.2011, p. 28-32.

Research output: Contribution to journalArticle

Heinzerling, John H. ; Kavanagh, Brian ; Timmerman, Robert D. / Stereotactic ablative radiation therapy for primary lung tumors. In: Cancer Journal. 2011 ; Vol. 17, No. 1. pp. 28-32.
@article{03e4ae93f971447a8f122b509a5eb1dd,
title = "Stereotactic ablative radiation therapy for primary lung tumors",
abstract = "Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.",
keywords = "innovative therapy, non-small cell lung cancer (NSCLC), stage I lung cancer, Stereotactic ablative radiotherapy (SABR), stereotactic body radiation therapy",
author = "Heinzerling, {John H.} and Brian Kavanagh and Timmerman, {Robert D.}",
year = "2011",
month = "1",
doi = "10.1097/PPO.0b013e31820a7f80",
language = "English (US)",
volume = "17",
pages = "28--32",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Stereotactic ablative radiation therapy for primary lung tumors

AU - Heinzerling, John H.

AU - Kavanagh, Brian

AU - Timmerman, Robert D.

PY - 2011/1

Y1 - 2011/1

N2 - Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.

AB - Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.

KW - innovative therapy

KW - non-small cell lung cancer (NSCLC)

KW - stage I lung cancer

KW - Stereotactic ablative radiotherapy (SABR)

KW - stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=79551573509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551573509&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31820a7f80

DO - 10.1097/PPO.0b013e31820a7f80

M3 - Article

C2 - 21263264

AN - SCOPUS:79551573509

VL - 17

SP - 28

EP - 32

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 1

ER -